ABSTRACT
Introduction
Neuroblastoma is the most common solid extra cranial malignancy in children younger than 15 years. It accounts for 8% -10% of all childhood cancers and 15% of cancer deaths in children [1] . Although this tumor is chemo-and radio-sensitive, it is prone to relapse after initial induction of remission. Stage I and II tumours can be cured with surgery alone, whilst stage III tumours require preoperative chemotherapy. Sixty percent of neuroblastomas in children are diagnosed in stage IV, of whom many have biological markers of poor prognosis, such as MYCN amplification or 1p deletion [2] . One of the major goals of cancer treatment is to develop therapies affecting cancer cells while causing little or no damage to the normal counterparts. In this perspective numerous attempts have been made to bind anti-tumor compounds or radioactive isotopes to molecules specifically taken up by tumour cells. One example of these molecules is meta-iodobenzylguanidine (MIBG), a norepinephrine analogue which is taken up by organs rich in adrenergic innervation and/or catecholamine excretion. Therefore, I-131 radio-labelled MIBG allows successful imaging of these organs and neuroectodermally derived tumors, such as neuroblastomas, pheochromocytomas, paragangliomas, medullary thyroid carcinoma, carcinoid tumors and Merkel cell skin tumors. The use of radiolabelled MIBG to treat neuroectodermally derived tumors have arisen from the high sensitivity and specificity of in vivo MIBG imaging for detection of primary and metastatic tumours [3] .
Radio-labelled MIBG therapy is most commonly used in the treatment of neuroblastoma, which is a high grade malignancy of childhood [3] . I-131MIBG was initially reserved for palliation of patients with recurrent disease. However, clinical trials evaluating the role of 131I-MIBG as a first line drug, either as a single agent, or in combination with chemotherapy or myeloablation treat-ment, or in consolidation treatment have been performed with mixed results and significant potential side effects. The response rates varied between 20% and 60% in newly diagnosed and relapsed or refractory patients [4] [5] [6] [7] [8] [9] .
Despite all this information the precise role of 131I-MIBG in the overall therapeutic strategy of neuroblastoma is far from being defined. In particular, it is still unclear whether I-131MIBG might improve the tumour response of patients who did not achieve complete remission with conventional therapy and are therefore predisposed to disease progression and death.
We conducted this retrospective study to present the experience of the National Cancer Institute, Cairo-Egypt with I-131MIBG therapy in neuroblastoma and to determine the impact of MIBG therapy on patients' outcome especially their quality of life. This study has been approved by the NCI ethics and research committee.
Patients and Methods
The study included 42 paediatric patients treated and followed up at the National Cancer Institute (NCI), Cairo University between March 1998 and Dec. 2008. All patients had a confirmed histopathology of neuroblastoma. Twelve patients (28.5%) had stage III disease and 30 (71.5%) were stage IV disease. Twenty five of the study patients (59.5%) were males and 17 (40.5%) were females. Their age ranged from 12 months to 11 years, with a mean of 4.8 ± 3.1 years. Frequencies of the disease primary sites were as follows: 29 (69%) patients with supra-renal neuroblastoma, 7 (16.6%) retro-peritoneal, 4 (16.6%) para-vertebral and 2 (4.7%) pre-sacral. Lymph node spread was seen in 9/12 patients of stage III disease. Bone deposits were detected in 26 patients. Hepatic deposits were present in 5 patients and brain metastasis was present in only one patient.
All the patients did I-131 MIBG total body scan before attempting I-131 MIBG therapy. All had residual tumour in the diagnostic scan at end of first-line therapy in both stage III and IV disease. Residual tumour was detected either at the primary site of the tumour and/or other metastatic lesions .
Further Eligibility criteria for I-131 MIBG therapy included normal CBC, liver and kidney functions. 
Patient Preparation before I-131 MIBG Therapy

I-131 MIBG Therapy
The administered doses of I-131 MIBG ranged from 100 mCi for children weighing less than 20 kg, up to 150 mCi for children weighing more than 20 kg. Specific activity ranged from 1.4 to 2.3 GBq·mg -1 (mean 1.8). I-131 MIBG dose is injected in 100 ml saline or 100 ml 5% dextrose over 45 minutes. Close relatives actively participated in nursing care were provided with digital pocket dosimeter for radiation exposure monitoring after explaining radiation safety guidelines to them. Patients were discharged usually when the exposure rate at 1 meter is less than 30 mR/hr. Once discharged they were checked weekly clinically and through laboratory tests for haematological indices, kidney & liver functions to monitor any toxicity. Any Toxic effects attributable to I-131 MIBG therapy were reported. The treatment was repeated every 4 -6 weeks. Assessment of primary tumour and metastasis response was done after the third I-131 MIBG therapy course unless evidence of progressive disease or toxic side effects had occurred.
In case of either disease improvement or stability after the third I-131 MIBG course, additional courses with an interval of 4 -6 weeks between courses were administered.
Evaluation of Tumour Response
Tumour response was defined as follows:  Complete response (CR), disappearance of primary tumour and of all metastatic lesions with normalization of urine catecholamines;  Very good partial response (VGPR), >90% volume reduction of the primary tumour with clearing of all measurable metastatic lesions with the exception of residual changes at skeletal scintigraphy, normalization of urine catecholamines;  Partial response (PR), >50% volume reduction of the primary tumour and of all measurable metastatic lesions,  Stable disease (SD), <50% reduction but <25% increase in any existing lesion.  Progressive disease (PD), increase >25% of any measurable lesion or appearance of a new lesion [10] . Isolated decrease of I-131 MIBG uptake was not con-sidered evidence of tumour response. Response was evaluated as mentioned before 3 -4 weeks following the third I-131 MIBG course by means of CT scan, and urinary catecholamines.
Quality of life: we intended to monitor changes in patients quality of life (him-herself & relatives) in terms of degree of pain relief, ability of move and play and psychological burden.
Results
The 42 patients included in this study were arranged in two groups; Group I included 12 patients with stage III neuroblastoma, Group II included 30 patients with stage IV neuroblastoma.
Group I
Twelve patients out of the 42 patients included in this study were stage III disease All had partial tumour response to first-line treatment. Before I-131MIBG therapy 6 patients underwent surgery consisting of partial tumour resection in 3 patients, exploration & biopsy in two patients and near total resection in the remaining patient with histological evidence of viable tumour cells in all surgical specimens.
Before starting I-131 MIBG all the patients showed elevated level of urinary catecholamine excretion & pathological scintigraphic I-131 MIBG uptake at the site of the primary. Main patients' data are listed in Table 1 .
Five patients received six I-131 MIBG courses, three patients received two courses and the remaining four patients: one received eight courses, one received 7 courses, one received five courses and one received two courses.
The interval between courses ranged from 4 to 6 weeks. One patient showed complete response (case no. 5) and is still alive disease free 132 month later. Five patients had partial response four of these five patients are alive with stable disease (cases no. 1, 6, 7, 9,) for 38 -67 months (mean 50.5) (Figures 1(a)-(b) ), and one patient (case no. 8) showed progressive disease and is alive for 21 months. The remaining 6/12 patients remained with stable disease with I-131 MIBG therapy. Five patients out of these six showed progressive disease and three of them died (cases no. 2, 3, 4) and 2 are alive (cases no. 10, 12) for 20, 46 months. The remaining patient (case no. 11) remained stable and is alive for 46 months (Figures 2(a)-(b) ).
Progressive disease was determined by appearance of new osseous deposits in I-131 MIBG scan, bone scan as well as increase in level of urinary catecholamine, while patients with stable disease showed no further progression in tumour by CT or in the I-131 MIBG scan and no increase in level of urinary catecholamines.
No further anti-tumour therapy was administered to all the patients of this group in conjunction with I-131 MIBG therapy.
The 5 year event free survival (EFS) of this group is 46.6% (Figure 3 ) and the overall survival is 75% with follow-up of 8 -132 months (median, 38) (Figure 4). 
Group II
Thirty patients out of the 42 patients included in this study were stage IV disease who achieved partial response with first-line therapy. Ten of them underwent partial surgical resection. Scintigraphy performed before I-131MIBG therapy was positive at the primary site and metastatic lesions{bone deposits (26 patients), hepatic deposits (5 patients)}. Main patient data are summarized in Table 2 . Two patients received one I-131MIBG course of therapy, 4 received twocourses, 13 received three courses, one received four courses, two received five courses, six received six courses and two received seven courses. Intervals between courses as mentioned ranged from 4 to 6 weeks. (Figures 5(a)-(b) ).
The 5-year EFS of this group is 48.2% ( Figure 6 ) and overall survival is 69% (Figure 7 ) with follow up period of 8 -69 months. (median 22).
Nearly the same results are achieved in the 2 groups under study (stage III and stage IV disease). This may be attributed to the fact that stage III disease patients are already advanced from the start, also may be because we used the same small doses of MIBG for both groups. May be it would had been a good idea to give larger doses related to the tumour burden. However this approach might have increased the toxicity.
We noticed marked improvement in pain in 22 patients out of the 26 patients with bone metastasis (84.5%). Thirty two out of the 42 patients (76%) included in this study showed better quality of life in the form of pain relief, enjoying longer time of playing without treatment burden , enjoying life with no toxic effects of therapy as well as partially relieving the psychological burden of the children and their parents. CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.
Discussion
Long-term survival of children with inoperable or disseminated neuroblastoma diagnosed after the age of one year remains largely unsatisfactory mainly because chemotherapy treatment usually fails to eradicate the disease [11] [12] [13] . Thus, alternative therapies are being trialled for the benefit of increasing long term survival and improving quality of life. Radiolabelled benzylguanidine with Iodine 131 has been used in the treatment of neural crest tumours and seemed suitable due to it's physical characteristics. The radiation emitted from I-131 proved to be ffective to induce damage of large tumour lesions [14] . e I-131 MIBG therapy for neuroblastoma has been used since the late 1980 and demonstrated objective tumour responses in 20% -60% of patients failing to respond to chemotherapy treatment protocols [15] [16] [17] . In addition, significant pain relief was noticed even in patients who did not exhibit objective responses [18] . Similarly in the present study, we noticed marked improvement in pain in 22 (84.5%) patients out of the 26 patients with bone metastasis. Thirty two patients out of the 42 (76%) patients included in this study showed better quality of life in the form of pain relief, enjoying longer time of playing without treatment burden, enjoying life with no toxic effects of therapy as well as partially relieving the psychological burden of the children and their parents.
Lastly, attempts are being made to evaluate whether I-31 MIBG given as front-line therapy may improve the 1 outcome of these patients without causing excessive toxicity [18, 19] . To our knowledge, no prospective study has been carried out so far to evaluate the true potential value of I-131MIBG therapy and to identify the group of patients who may profit best from this treatment modality. The difficulties in design of such studies include the high cost of the drug, many centres do not possess the facilities to deliver this treatment to young patients, and the burden of keeping patient in a radiation protected environment with limited parental contact extended for few days. Garaventa et al., 1991 , studied 31 patients treated with I-131MIBG after disease relapse or progression. They reported that the rate and degree of responses were lower in the presence of bulky disease, a high number of MIBG-positive lesions, long duration of previous therapy and overt bone marrow infiltration [11] .
On 1999, Garaventa et al., published their work on MIBG therapy in children with high-risk neuroblastoma who responded to first-line therapy without achieving CR, provided that the residual primary tumour and/or metastases were clearly MIBG avid. They reported that MIBG therapy showed very good partial response in 4/13 patients with stage III neuroblastoma, 1 patient showed disease progression and 8 patients showed stable disease. Regarding stage IV patients, 1/30 patients showed CR, 10 patients showed PR, 15 patients had no response to MIBG therapy and 4 patients showed progressive disease [20] . They stated the 5-year event-free survival (EFS) of stage III neuroblastoma to be 92% (±0.07) and that of stage IV to be 40% (±0.08) [20] .
In the present study, our results indicate that patients with stage III disease did benefit from MIBG therapy. One patient showed complete response and is still alive disease free 132 month later, five patients had partial response, four of them are alive, and the remaining 6 patients remained stable with three of them alive. The 5 years event free survival (EFS) of stage 3 patients was 46.6 % and the overall survival was 75%.
Regarding stage IV patients, two patients achieved CR and are still alive disease-free 64 and 69 months later. Nine patients showed PR to I-131 MIBG, all the nine patients are alive at 16 -57 months (mean 30.6) among whom seven are alive with stable disease and two patients are alive with progressive disease. Eighteen patients remained stable after I-131 MIBG therapy, among them six are alive with PD and four are alive with stable disease, while the remaining eight patients died. The last patient developed PD and died within 15 months. The 5 years event free survival (EFS) of stage IV patients was 48.2% and the overall survival was 69%.
Our results are different from Garaventa et al., 1999 concerning stage III neuroblastoma, this may be attributed to the fact that stage III disease patients are already advanced from the start, also may be because we used the same doses of MIBG for both groups [20] .
Conclusions
We conclude that I-131 MIBG therapy has favourable therapeutic effects that are translated into an overall improved outcome with good quality of life. To our opinion improving quality of life is one of great achievement of I-131 MIBG therapy.
Controlled clinical trials should be considered to evaluate the true potential of I-131 MIBG therapy.
